Risteys ·

OMOP concept ID	Test name	Measurement unit (harmonized unit)	N people	N records	Missing measurement value	Harmonized value distribution	Test outcome NA N A AA L LL H HH
3014300	s-b2gpabm	— (—)	894	1018	100.00%	Distribution not available
3014300	s-b2gpabm	kU/l (u/ml)	95	111	57.66%

LabWAS

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

Venous thromboembolism

269

335

7.79

190.83

1.2

1.1

29.82

30.33

u/ml

0.01

DVT of lower extremities and pulmonary embolism

218

275

7.96

159.83

1.2

1.1

32.10

40.00

u/ml

—

ILD medications: immunosuppressive drugs

254

491

4.71

106.32

1.2

41.64

18.31

u/ml

1.02

Pulmonary heart disease

151

211

7.22

101.98

1.2

1.1

28.29

31.88

u/ml

—

Pulmonary heart disease, diseases of pulmonary circulation

156

227

6.93

101.52

1.2

1.1

28.29

31.88

u/ml

—

Pulmonary embolism

151

213

7.15

101.12

1.2

1.1

28.29

31.88

u/ml

—

Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified (FINNGEN)

177

163

6.88

92.75

1.2

26.50

53.60

u/ml

—

Cardiovascular diseases (excluding rheumatic etc)

230

276

4.79

82.04

1.2

26.10

40.13

u/ml

—

Inflammatory bowel disease treatment related agents

340

583

3.24

73.04

1.1

1.2

33.53

22.30

u/ml

0.42

Oral corticosteroids

316

567

3.28

70.35

1.1

1.2

33.80

22.30

u/ml

0.44

ILD medications

326

548

3.21

68.41

1.1

1.2

43.07

17.82

u/ml

1.17

Reimbursement for rheumatic diseases

199

508

3.91

67.69

1.2

1.1

39.07

17.67

u/ml

0.93

Cardiovascular diseases

202

232

4.64

67.44

1.2

1.1

43.63

22.57

u/ml

—

Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

294

617

3.22

66.84

1.2

41.33

16.50

u/ml

1.25

STROKE

182

268

4.59

66.54

1.2

1.1

13.09

50.43

u/ml

—

ILD medications: prednisolone, methylprednisolone, prednisone

311

541

3.20

65.69

1.1

1.2

37.00

17.82

u/ml

0.74

Coagulation defects, purpura and other haemorrhagic conditions

105

177

5.99

59.41

1.3

1.1

41.90

21.33

u/ml

—

Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified

268

537

3.16

58.09

1.2

29.15

28.22

u/ml

0.03

First line medication for Crohn's disease

304

542

3.02

58.05

1.1

1.2

35.60

22.95

u/ml

—

Systemic connective tissue disorders

132

291

4.56

55.19

1.3

1.1

38.08

23.00

u/ml

—

Autoimmune diseases excluding thyroid diseases, strict definition

272

491

3.02

52.11

1.2

35.00

16.67

u/ml

0.76

Autoimmune diseases excluding thyroid diseases

276

507

2.96

51.02

1.2

33.14

16.67

u/ml

0.72

L04AX Other immunosuppressants

183

545

3.37

50.13

1.2

47.30

17.75

u/ml

—

Second line medication for Crohn's disease

185

569

3.26

48.10

1.2

47.30

17.14

u/ml

—

Ischaemic Stroke, excluding all haemorrhages

150

281

3.94

47.19

1.2

1.1

13.00

30.25

u/ml

—

Stroke, excluding SAH

158

302

3.79

46.81

1.2

1.1

13.00

42.00

u/ml

—

Autoimmune diseases related-to ILD

233

697

2.80

44.53

1.2

34.53

21.05

u/ml

0.56

Cerebrovascular diseases

187

397

3.27

44.30

1.2

1.1

13.00

33.29

u/ml

—

Stroke, including SAH

160

323

3.56

43.51

1.2

1.1

13.00

42.00

u/ml

—

Hypertensive diseases (excluding secondary)

130

172

4.41

42.97

1.2

28.20

53.60

u/ml

—

Finngen Rheumatological endpoints

257

541

2.70

41.34

1.2

33.25

20.23

u/ml

0.56

Autoimmune diseases

261

510

2.60

37.79

1.1

1.2

45.78

16.67

u/ml

—

Hard cardiovascular diseases

197

396

2.95

37.46

1.2

1.1

16.91

37.29

u/ml

0.85

Used for control exclusion in common control thyroid runs

240

474

2.56

33.63

1.2

50.25

16.67

u/ml

—

Diseases of arteries, arterioles and capillaries (FINNGEN)

6.46

29.37

1.2

1.1

14.60

—

u/ml

—

Persons with potential health hazards related to family and personal history and certain conditions influencing health status

238

648

2.32

29.33

1.1

1.2

12.00

35.35

u/ml

—

Polyarthropathies

166

411

2.60

26.01

1.1

1.2

51.33

19.75

u/ml

—

Neurological diseases, wide definition

4.63

25.97

1.2

24.60

—

u/ml

—

GASTRO-related operations

179

349

2.58

25.58

1.1

1.2

42.17

20.64

u/ml

—

Any gastric operation

179

349

2.58

25.58

1.1

1.2

42.17

20.64

u/ml

—

Abnormalities of breathing

214

530

2.31

25.48

1.1

1.2

25.60

29.28

u/ml

—

Episodal and paroxysmal disorders

232

520

2.27

25.47

1.1

1.2

18.20

40.00

u/ml

—

Neurological diseases

188

382

2.48

24.85

1.1

1.2

25.20

42.83

u/ml

—

Sleep apnoea, including avohilmo

219

599

2.21

23.98

1.1

1.2

17.00

28.11

u/ml

—

Other soft tissue disorders, not elsewhere classified

222

571

2.21

23.93

1.2

32.40

27.09

u/ml

—

Dyspnoea

201

658

2.21

22.88

1.2

26.43

28.07

u/ml

—

Sleep apnoea

203

575

2.23

22.86

1.1

1.2

18.40

27.52

u/ml

—

Renal failure

104

303

2.93

22.04

1.1

38.44

20.44

u/ml

—

Transient ischemic attack

105

285

2.94

22.01

1.2

1.1

13.88

33.29

u/ml

—

Dermatitis

152

626

2.38

21.98

1.1

1.2

23.20

26.43

u/ml

—

Other systemic involvement of connective tissue

228

3.39

21.62

1.2

1.1

50.14

26.83

u/ml

—

All kidney diseases

220

708

2.08

21.36

1.2

37.86

19.55

u/ml

0.74

Chronic kidney disease

215

3.32

19.97

1.2

1.1

46.86

23.17

u/ml

—

Pain in limb

190

560

2.16

19.95

1.2

24.56

27.09

u/ml

—

Other and unspecified dermatitis

130

538

2.42

19.70

1.1

23.20

26.17

u/ml

—

General symptoms and signs

216

536

2.02

18.06

1.2

47.00

23.48

u/ml

—

Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium

109

258

2.67

18.04

1.2

53.83

28.00

u/ml

—

Migraine

129

422

2.38

17.94

1.1

1.2

16.17

45.14

u/ml

—

Other neurological diseases

144

493

2.27

17.91

1.2

1.1

13.89

32.65

u/ml

—

All chronic kidney diseases

113

359

2.51

17.72

1.2

1.1

51.11

18.10

u/ml

—

Other obstetric conditions, not elsewhere classified

110

265

2.63

17.68

1.2

53.83

28.00

u/ml

—

Explicit Sepsis

332

2.67

17.65

1.2

1.1

22.80

41.64

u/ml

—

Explicit Sepsis, including avohilmo

336

2.65

17.59

1.2

1.1

22.80

41.64

u/ml

—

Parasetamol

147

318

2.34

17.51

1.1

1.2

27.40

28.69

u/ml

—

Sleep disorders (combined)

227

609

1.95

17.41

1.1

1.2

17.40

29.34

u/ml

—

Other bacterial diseases

187

606

2.05

17.37

1.2

28.83

25.16

u/ml

0.11

Renal tubulo-interstitial diseases

185

671

2.02

17.05

1.1

1.2

40.83

19.25

u/ml

0.77

Other bacterial diseases, including avohilmo

209

668

1.95

16.92

1.2

28.62

26.27

u/ml

0.08

Hypertension, essential

161

421

2.16

16.61

1.1

1.2

26.67

25.71

u/ml

—

Hypertension

165

435

2.14

16.58

1.1

1.2

24.67

25.71

u/ml

—

Hypertensive diseases

164

435

2.13

16.26

1.1

1.2

26.50

25.71

u/ml

—

Rheumatoid arthritis

223

2.95

16.11

1.1

29.00

26.80

u/ml

—

Diseases of arteries, arterioles and capillaries

123

392

2.30

15.73

1.2

1.1

15.29

36.17

u/ml

—

Abnormal findings on examination of blood, without diagnosis

100

375

2.42

14.94

1.2

1.1

23.20

28.57

u/ml

—

Arthropathies

188

493

1.93

14.01

1.1

1.2

44.71

23.24

u/ml

—

Heart failure, not strict

133

420

2.13

13.90

1.2

1.1

28.89

26.57

u/ml

—

Opioids

201

554

1.88

13.88

1.1

1.2

16.00

32.32

u/ml

—

Persons encountering health services in other circumstances, wide

214

602

1.83

13.67

1.1

1.2

18.50

29.32

u/ml

—

Implicit bacterial Sepsis, including avohilmo

292

2.48

13.55

1.1

19.71

28.70

u/ml

—

Azathioprine

119

3.63

13.52

1.2

—

24.00

u/ml

—

Codeine or tramadol medication

226

691

1.78

13.38

1.2

13.20

29.37

u/ml

—

Condition for Implicit Sepsis (Organ dysfunction codes)

159

563

1.96

13.38

1.1

18.56

33.16

u/ml

—

Other heart diseases, wide

190

619

1.86

13.31

1.1

1.2

19.13

27.28

u/ml

—

Bacterial Sepsis

312

2.36

12.48

1.1

19.71

28.70

u/ml

—

Rheumatoid arthritis, including avohilmo

349

2.38

12.35

1.1

29.00

34.75

u/ml

—

Pain (limb, back, neck, head abdominally)

136

330

2.07

12.27

1.2

39.80

25.00

u/ml

—

Dermatitis and eczema

214

730

1.74

12.01

1.2

30.45

25.00

u/ml

0.14

Symptoms and signs involving the circulatory and respiratory systems

192

532

1.81

11.88

1.2

27.33

29.28

u/ml

—

Disorders of thyroid, IBD co-morbidities

3.82

11.81

1.1

1.2

—

u/ml

—

Implicit Sepsis, including avohilmo

149

558

1.91

11.80

1.1

19.71

31.38

u/ml

—

Implicit bacterial Sepsis

271

2.44

11.71

1.2

1.1

19.71

28.70

u/ml

—

Soft tissue disorders

199

574

1.78

11.68

1.2

21.57

27.09

u/ml

—

Diseases of the skin and subcutaneous tissue

181

496

1.83

11.66

1.1

1.2

50.11

14.89

u/ml

—

Metabolic disorders

175

580

1.81

11.37

1.1

1.2

13.43

31.22

u/ml

—

Implicit Sepsis

134

509

1.94

11.24

1.1

21.67

32.30

u/ml

—

Bacterial infection, other or unspecified

378

2.17

11.23

1.1

42.00

31.45

u/ml

—

Heart failure,strict

269

2.29

11.08

1.2

1.1

20.29

18.67

u/ml

—

Ischemic heart diseases

139

429

1.93

10.96

1.1

19.13

28.22

u/ml

—

Spondylopathies

141

440

1.90

10.56

1.1

1.2

14.20

32.00

u/ml

—

Varicose veins

346

2.12

10.41

1.2

1.1

13.33

29.27

u/ml

—

Heart failure, strict

298

2.17

10.40

1.2

1.1

20.29

24.67

u/ml

—

Other disorders of bladder

3.81

10.19

1.2

1.1

—

15.20

—

All-cause Heart Failure

297

2.16

10.14

1.2

1.1

20.29

24.67

u/ml

—

Condition for Implicit Sepsis (Organ dysfunction codes), including avohilmo

163

625

1.76

9.98

1.1

1.2

19.80

32.82

u/ml

—

Abnormal findings on diagnostic imaging and in function studies, without diagnosis

117

530

1.92

9.92

1.2

1.1

63.00

18.86

u/ml

—

Atrial fibrillation and flutter with reimbursement

3.96

9.89

1.2

—

u/ml

—

Other CVD (FINNGEN)

5.35

9.76

1.3

1.2

—

Bacterial infection, other or unspecified, including avohilmo

102

417

2.01

9.67

1.1

42.00

27.14

u/ml

—

Erysipelas, including avohilmo

123

490

1.86

9.21

1.1

28.67

27.80

u/ml

—

Acute renal failure

164

2.75

9.09

1.0

1.1

12.00

25.80

u/ml

—

Disorders of gallbladder, biliary tract and pancreas

175

650

1.68

8.90

1.1

1.2

43.33

18.13

u/ml

—

Bronchitis

201

746

1.62

8.83

1.2

12.60

28.94

u/ml

—

Exposure to unspecified factor

187

786

1.62

8.49

1.1

1.2

15.33

28.93

u/ml

—

Intracerebral haemorrhage

4.16

8.44

1.2

—

u/ml

—

Heart failure and bmi 25plus

189

2.30

8.30

1.2

1.1

22.00

10.20

u/ml

—

Hypothyreosis and Thyroxine purchase for inclusion criteria

173

691

1.64

8.24

1.1

1.2

41.00

25.45

u/ml

—

Erysipelas

402

1.95

8.16

1.1

29.20

33.58

u/ml

—

Persons encountering health services for other counselling and medical advice, not elsewhere classified

184

602

1.62

8.08

1.1

1.2

20.83

29.32

u/ml

—

Hypothyroidism, other/unspecified

167

669

1.64

8.00

1.1

1.2

41.00

24.25

u/ml

—

Diarrhoea and gastroenteritis of presumed infectious origin, including avohilmo

181

732

1.59

7.55

1.1

1.2

21.57

27.90

u/ml

—

Complications of procedures, not elsewhere classified

145

705

1.66

7.51

1.2

20.67

29.62

u/ml

—

Disorders of choroid and retina

130

530

1.72

7.49

1.1

24.20

29.45

u/ml

—

Major coronary heart disease event

126

432

1.75

7.44

1.1

19.50

27.20

u/ml

—

Symptoms and signs involving the digestive system and abdomen

166

509

1.64

7.42

1.2

51.29

21.96

u/ml

—

Visual disturbances

487

1.87

7.41

1.1

21.20

30.40

u/ml

—

Certain infectious and parasitic diseases, including avohilmo

129

369

1.75

7.40

1.2

27.33

20.58

u/ml

—

Peripheral artery disease

230

2.17

7.35

1.2

1.1

18.00

27.22

u/ml

—

Acute tubulo-interstitial nephritis

109

523

1.76

7.10

1.1

30.17

17.54

u/ml

—

Symptoms and signs involving the skin and subcutaneous tissue

131

746

1.66

7.02

1.1

1.2

49.00

22.72

u/ml

—

Complications of surgical and medical care, not elsewhere classified

174

740

1.57

7.02

1.2

20.33

28.78

u/ml

—

Pneumonia, organism unspecified

160

688

1.60

6.96

1.1

1.2

31.00

27.23

u/ml

—

Genitourinary diseases

261

1.87

6.82

1.2

31.00

21.31

u/ml

—

Other pulmonary diagnosis

139

417

1.67

6.79

1.1

1.2

26.60

29.94

u/ml

—

Certain infectious and parasitic diseases

172

545

1.58

6.78

1.2

45.00

19.21

u/ml

—

GI-bleeding

256

2.15

6.64

1.1

—

18.73

u/ml

—

Visual disturbances and blindness

512

1.80

6.64

1.1

21.20

30.40

u/ml

—

Infections of the skin and subcutaneous tissue

109

627

1.71

6.63

1.2

41.57

27.86

u/ml

—

Excluding asthma or asthma-COPD overlap

138

417

1.66

6.58

1.1

1.2

27.33

29.94

u/ml

—

154

564

1.60

6.55

1.2

33.78

26.91

u/ml

—

COPD/asthma/ILD related pneumonia or pneumonia derived septicaemia

154

564

1.60

6.55

1.2

33.78

26.91

u/ml

—

Coronary atherosclerosis

321

1.83

6.52

1.1

11.40

20.88

u/ml

—

COPD differential diagnosis

137

415

1.66

6.48

1.1

1.2

24.57

31.31

u/ml

—

ILD differential diagnosis

137

415

1.66

6.48

1.1

1.2

24.57

31.31

u/ml

—

COPD/asthma/ILD related infections

174

564

1.55

6.26

1.1

1.2

41.57

26.91

u/ml

—

COPD/asthma related infections

174

564

1.55

6.26

1.1

1.2

41.57

26.91

u/ml

—

Internal derangement of knee

323

1.96

6.09

1.1

1.2

—

22.82

u/ml

—

Hypo-osmolality and hyponatraemia

116

2.66

5.97

1.1

—

28.33

u/ml

—

Diseases of oesophagus, stomach and duodenum

183

721

1.50

5.95

1.1

1.2

53.50

21.30

u/ml

—

Other CVD

135

2.52

5.92

1.2

1.1

—

12.50

u/ml

—

Viral infections characterized by skin and mucous membrane lesions, including avohilmo

158

806

1.53

5.88

1.2

23.20

27.23

u/ml

—

Traumatic subarachnoid haemorrhage

9.22

5.79

1.1

1.2

—

All pneumoniae

175

760

1.50

5.76

1.1

1.2

28.88

26.63

u/ml

—

Pneumonias (Asthma/COPD co-morbidities)

174

759

1.50

5.76

1.1

1.2

28.88

26.63

u/ml

—

Abdominal and pelvic pain

157

509

1.55

5.75

1.2

33.60

21.96

u/ml

—

Other diseases of the digestive system

259

2.05

5.70

1.1

—

18.73

u/ml

—

Chronic apical periodontitis

191

728

1.47

5.65

1.1

1.2

36.14

25.44

u/ml

—

Statin medication

124

432

1.62

5.58

1.2

21.20

35.60

u/ml

—

Other/unspecified cytomegaloviral diseases

10.12

5.54

1.1

—

189

651

1.47

5.49

1.1

1.2

12.60

28.75

u/ml

—

Dental caries, including avohilmo

113

350

1.65

5.44

1.1

1.2

17.60

21.38

u/ml

—

Medical treatment for female infertility

292

1.94

5.27

1.2

—

41.45

u/ml

—

Lower back pain or/and sciatica

183

782

1.45

5.25

1.1

1.2

10.43

30.59

u/ml

—

Ischaemic heart disease, wide definition

109

411

1.63

5.23

1.1

13.71

29.24

u/ml

—

Diseases of the respiratory system

110

335

1.65

5.20

1.1

1.2

26.40

32.29

u/ml

—

Pneumonia (excl. viral and due to other infectious organisms not elsewhere classified)

167

755

1.47

5.17

1.1

1.2

24.86

27.71

u/ml

—

Other diseases of intestines

184

707

1.45

5.09

1.1

1.2

17.60

29.96

u/ml

—

Influenza and pneumonia

179

762

1.45

5.05

1.2

28.88

26.63

u/ml

—

Psychiatric diseases

161

541

1.49

5.02

1.1

1.2

40.33

26.60

u/ml

—

Cholelithiasis, broad definition with cholecystitis

139

609

1.52

5.01

1.1

1.2

30.86

18.57

u/ml

—

Intestinal infectious diseases, including avohilmo, including avohilmo

187

725

1.44

4.94

1.1

1.2

21.71

28.54

u/ml

—

Other noninfective gastroenteritis and colitis

233

2.02

4.91

1.2

1.1

—

23.64

u/ml

—

AV-block

2.59

4.86

1.1

—

14.60

u/ml

—

Cytomegalovirus infection, IBD co-morbidity

7.77

4.86

1.1

1.2

—

Acute upper respiratory infections

172

712

1.45

4.82

1.1

1.2

22.40

28.59

u/ml

—

Implicit viral Sepsis, including avohilmo

263

1.94

4.76

1.1

—

31.67

u/ml

—

Diseases of pulp and periapical tissues, including avohilmo

165

586

1.46

4.65

1.1

1.2

31.17

28.04

u/ml

—

Asthma, including avohilmo

194

759

1.41

4.61

1.1

1.2

18.86

28.55

u/ml

—

Disease of hard tissues of teeth, NOS

271

1.68

4.55

1.2

23.33

19.64

u/ml

—

Other disorders of skin and subcutaneous tissue, not elsewhere classified

104

2.51

4.53

1.2

1.1

—

14.60

—

Dorsalgia

161

593

1.44

4.31

1.1

1.2

11.43

34.13

u/ml

—

Cholelithiasis

129

595

1.48

4.20

1.1

1.2

30.86

18.20

u/ml

—

Vascular diseases of the intestine

6.95

4.16

1.0

1.3

—

u/ml

—

Hypotension

104

2.41

4.04

1.3

1.2

—

12.50

—

Pneumocystosis, including avohilmo

10.08

4.01

1.3

1.1

—

u/ml

—

Pneumocystosis

10.08

4.01

1.3

1.1

—

u/ml

—

Other diseases of intestine

118

2.29

3.93

1.1

—

17.33

u/ml

—

Other spirochaetal diseases

359

0.33

3.91

1.1

—

39.21

u/ml

—

Chronic lower respiratory diseases

195

753

1.36

3.89

1.1

1.2

20.50

27.90

u/ml

—

Enlarged lymph nodes

125

2.24

3.88

1.1

—

22.00

u/ml

—

Lyme disease

356

0.34

3.85

1.1

—

39.21

u/ml

—

Lyme disease, including avohilmo

356

0.34

3.85

1.1

—

39.21

u/ml

—

Benign paroxysmal vertigo

270

1.82

3.84

1.1

—

32.38

u/ml

—

Other specified/unspecified necrotizing vasculopathies

12.12

3.77

1.0

1.2

—

Viral and other specified intestinal infections

216

1.90

3.77

1.3

1.2

—

25.38

u/ml

—

Type 2 diabetes, wide definition

114

485

1.48

3.74

1.1

20.40

26.06

u/ml

—

Other and unspecified effects of external causes

295

1.77

3.72

1.2

1.1

—

34.93

u/ml

—

Other spirochaetal diseases, including avohilmo

364

0.36

3.71

1.1

—

37.73

u/ml

—

Gonarthrosis [arthrosis of knee](FG)

355

1.54

3.66

1.1

1.2

12.80

16.50

u/ml

—

Spirochaetal infections, other/unspecified, including avohilmo

359

0.36

3.61

1.1

—

39.21

u/ml

—

Other disorders of amniotic fluid and membranes

166

1.98

3.45

1.0

1.2

—

25.00

u/ml

—

Conduction disorders

170

1.89

3.43

1.1

—

19.75

u/ml

—

Disorders of sclera, cornea, iris and ciliary body

584

1.51

3.41

1.2

1.1

19.80

27.96

u/ml

—

Cardiac arrest

6.18

3.41

1.3

—

Polyarteritis nodosa and related conditions

8.65

3.27

1.3

1.1

—

Injuries to the head

177

786

1.34

3.24

1.2

19.38

28.75

u/ml

—

Diabetic nephropathy

121

2.13

3.21

1.1

—

19.33

u/ml

—

Recurrent or chronic depression

275

1.62

3.18

1.2

—

34.81

u/ml

—

Persons encountering health services for specific procedures and health care

171

754

1.34

3.17

1.1

1.2

43.88

22.19

u/ml

—

Other disorders of kidney and ureter

111

2.17

3.12

1.1

—

13.67

u/ml

—

Polycystic ovarian syndrome, consortium definition

130

535

1.39

3.10

1.1

1.2

14.00

36.00

u/ml

—

Focal brain injury

4.01

3.08

1.2

—

Type 1 diabetes, wide definition

216

1.81

3.07

1.1

1.2

—

40.50

u/ml

—

Type 1 diabetes, wide definition, subgroup 1

209

1.82

3.06

1.1

1.2

—

40.50

u/ml

—

Systemic sclerosis,strict definition

10.12

2.99

1.0

1.4

—

105

2.13

2.98

1.1

—

27.71

u/ml

—

Cluster headache, strict

3.86

2.98

1.1

1.2

—

Necrosis of pulp, including avohilmo

100

693

1.43

2.97

1.2

20.67

30.00

u/ml

—

Hyperparathyroidism

134

2.00

2.86

1.0

1.1

—

13.71

u/ml

—

Adverse effects, not elsewhere classified

215

1.77

2.82

1.1

—

39.67

u/ml

—

Cluster headache, wide

3.59

2.78

1.1

1.2

—

Dermatitis herpetiformis

8.38

2.75

1.2

1.3

—

Charcot foot

8.38

2.75

1.2

—

IgA nephropathy (IgA glomerulonephritis)

5.03

2.73

1.1

—

Abnormalities of heart beat

307

1.61

2.70

1.1

—

39.00

u/ml

—

Any mental disorder

167

638

1.31

2.68

1.1

1.2

37.50

25.43

u/ml

—

Nerve, nerve root and plexus disorders

161

739

1.31

2.64

1.1

1.2

20.33

27.93

u/ml

—

Arthrosis

352

1.43

2.59

1.1

1.2

16.83

20.46

u/ml

—

Other diseases of anus and rectum

258

1.66

2.59

1.1

—

47.00

u/ml

—

Other disorders of bone

199

1.76

2.58

1.1

1.2

—

22.67

u/ml

—

Alcohol use disorder, Swedish definition

474

1.46

2.56

1.1

—

29.32

u/ml

—

Scarlet fever, including avohilmo

7.22

2.55

1.2

1.3

—

Crystal arthropathies, rheuma endpoint

7.18

2.55

1.0

—

u/ml

—

Drug-induced cataract

5.48

2.54

1.3

1.2

—

Presbycusis

2.39

2.47

1.1

—

11.40

—

Other bullous disorders

5.02

2.40

1.2

—

Other external causes of accidental injury

130

489

1.33

2.37

1.1

1.2

41.75

22.94

u/ml

—

Gonarthrosis

314

1.44

2.36

1.1

1.2

12.80

17.70

u/ml

—

Cirrhosis, broad definition used in the article https://doi.org/10.1101/594523

119

1.94

2.29

1.1

—

17.50

u/ml

—

Disorders of optic nerve and visual pathways

2.07

2.26

1.0

1.2

—

24.00

—

Diseases of the ear and mastoid process

175

692

1.27

2.24

1.2

12.67

30.89

u/ml

—

Diabetes, varying definitions

156

707

1.28

2.21

1.1

1.2

18.29

29.18

u/ml

—

Diabetes mellitus

157

711

1.28

2.17

1.1

1.2

18.29

29.18

u/ml

—

Hypocalcemia

4.31

2.15

1.2

1.1

—

Any death

376

1.41

2.15

1.1

13.83

27.60

u/ml

—

Abnormal findings on diagnostic imaging of other body structures

130

1.85

2.11

1.3

1.1

—

13.50

u/ml

—

Mycoses, including avohilmo

140

832

1.28

2.11

1.2

39.13

23.11

u/ml

—

Focal epilepsy

197

1.68

2.10

1.2

1.1

—

21.56

u/ml

—

Covid-19 suspected case

236

0.42

2.07

1.3

1.2

—

38.75

—

Neoplasms

129

520

1.30

2.07

1.2

54.80

19.40

u/ml

—

Schizophrenia

162

0.37

2.00

1.0

1.1

—

24.83

—

Viral and other specified intestinal infections, including avohilmo

322

1.50

2.00

1.2

—

34.64

u/ml

—

Focal epilepsy, mode (most common among epilepsy diagnosis)

171

1.70

1.95

1.1

—

22.14

u/ml

—

Iron deficiency anaemia secondary to blood loss (chronic)

112

1.88

1.95

1.1

—

16.00

u/ml

—

Fall on same level

176

756

1.24

1.95

1.1

1.2

47.57

22.37

u/ml

—

Accidents

126

489

1.29

1.92

1.2

46.71

22.94

u/ml

—

Focal epilepsy, strict definition

180

1.67

1.90

1.1

—

21.56

u/ml

—

Sarcoidosis

128

1.80

1.89

1.2

1.1

—

14.60

u/ml

—

Other condition

159

1.70

1.84

1.1

1.2

—

24.00

u/ml

—

Any mental disorder, or suicide (or attempt), or psychic disorders complicating pregnancy, partum or puerperum or nerve system disorders, excluding more controls

347

1.45

1.80

1.1

1.2

—

31.00

—

Inflammatory disease of uterus

176

1.65

1.78

1.1

—

51.33

u/ml

—

Use of hypnotics and sedatives

153

704

1.24

1.76

1.1

1.2

37.43

24.07

u/ml

—

Type 2 diabetes

145

672

1.25

1.76

1.1

1.2

17.88

29.89

u/ml

—

Fitting and adjustment of other devices

262

0.54

1.73

1.1

—

18.20

u/ml

—

Diabetes, insuline treatment (Kela reimbursement), excluding more controls

131

617

1.26

1.72

1.1

1.2

18.71

28.08

u/ml

—

Synovial cyst of popliteal space [Baker]

2.19

1.67

1.2

—

15.00

—

Diabetes, insulin treatment (Kela reimbursement)

138

661

1.24

1.63

1.1

1.2

18.71

27.46

u/ml

—

Persons encountering health services for specific procedures, not carried out

1.87

1.60

1.1

1.2

—

24.00

—

Nonsuppurative otitis media, including avohilmo

327

1.40

1.56

1.1

1.2

—

41.75

u/ml

—

Carbimazole or st.post thyroidectomy, condition for graves disease

231

1.52

1.56

1.1

—

38.67

u/ml

—

Pain and other conditions associated with female genital organs and menstrual cycle

229

1.46

1.47

1.3

1.2

—

31.30

u/ml

—

Any mental disorder, or suicide (or attempt), or psychic disorders complicating pregnancy, partum or puerperium or nerve system disorders

368

1.39

1.46

1.1

1.2

—

34.67

—

Congenital malformations of the nervous system

3.14

1.44

1.4

1.2

—

Hypertrophy of breast

204

1.52

1.42

1.1

—

60.20

u/ml

—

Injuries to the knee and lower leg

173

784

1.19

1.40

1.2

25.71

26.90

u/ml

—

Dermatophytosis

119

1.68

1.37

1.1

1.2

—

11.20

—

Hypertrophy of breast in women and men

223

1.48

1.35

1.1

—

42.50

u/ml

—

Insulin, fast-acting (human)

143

1.61

1.34

1.0

1.1

—

33.20

u/ml

—

Other female pelvic inflammatory diseases

175

1.54

1.34

1.3

1.1

—

51.50

u/ml

—

Diabetes medication

149

725

1.20

1.32

1.1

1.2

20.17

27.97

u/ml

—

Ectopic pregnancy

193

1.50

1.29

1.2

1.1

—

52.60

u/ml

—

False labour

253

1.35

1.28

1.2

—

20.67

u/ml

—

Noninfectious colitis NAS

123

1.63

1.23

1.3

1.1

—

24.00

u/ml

—

Mental and behavioural disorders due to alcohol, excluding acute intoxication

431

1.31

1.19

1.1

1.2

—

30.56

u/ml

—

Scabies, including avohilmo

166

1.51

1.14

1.2

—

47.67

u/ml

—

Lesion of ulnar nerve

126

1.59

1.14

1.0

1.2

—

17.50

u/ml

—

Nonsuppurative otitis media

230

1.40

1.13

1.2

1.1

—

31.00

u/ml

—

L02BA Anti-estrogens

151

1.52

1.11

1.2

1.1

—

47.20

u/ml

—

Other and unspecified urticaria

227

1.41

1.07

1.2

1.1

—

39.67

u/ml

—

Maternal care for known or suspected malpresentation of fetus

180

1.39

1.03

1.2

—

23.14

u/ml

—

Diseases of tongue

1.89

1.01

1.0

1.2

—

25.80

—

Artrosis, including avohilmo

112

514

1.19

0.99

1.2

34.13

20.12

u/ml

—

Procreative management

318

1.30

0.98

1.2

1.1

—

22.00

u/ml

—

LSIL lesion of the cervix uteri, vagina or vulva

175

0.57

0.98

1.1

1.2

—

52.20

—

Abnormal findings on antenatal screening of mother

116

1.55

0.96

1.1

1.2

—

31.86

u/ml

—

Excessive earwax

547

1.23

0.94

1.1

—

27.85

u/ml

—

Pediculosis, acariasis and other infestations, including avohilmo

200

1.40

0.93

1.3

1.2

—

42.14

u/ml

—

Gonarthrosis,primary

104

528

1.19

0.91

1.1

12.80

27.89

u/ml

—

Excessive attrition of teeth

755

1.19

0.90

1.2

22.60

28.52

u/ml

—

All influenza

237

1.35

0.87

1.1

1.2

—

34.23

u/ml

—

Unspecified/other endometriosis

118

1.50

0.83

1.1

1.2

—

35.20

—

Benign neoplasm: Ascending colon

111

0.54

0.83

1.0

1.1

—

16.14

—

Lateral epicondylitis

121

1.49

0.82

1.1

—

48.50

u/ml

—

Phobic anxiety disorders

154

1.43

0.82

1.1

1.2

—

48.43

—

COPD, hospital admission 2, with asthma infections

206

1.34

0.81

1.2

1.1

—

20.56

u/ml

—

Problems related to lifestyle

106

1.51

0.78

1.2

1.1

—

23.00

u/ml

—

Palmar fascial fibromatosis [Dupuytren]

0.52

0.78

1.0

1.1

—

23.67

—

Type 2 diabetes, definitions combined

123

623

1.15

0.75

1.1

1.2

16.71

26.84

u/ml

—

Primary hyperparathyroidism

1.54

0.75

1.1

—

17.33

u/ml

—

Other enthesopathies

288

1.28

0.75

1.1

—

30.40

u/ml

—

Enterocolitis due to Clostridium difficile

1.60

0.74

1.0

1.1

—

11.00

—

Lichen planus

116

1.47

0.74

1.1

—

13.50

—

Monoamine oxidase A inhibitors

108

1.48

0.73

1.1

—

13.67

—

Factors influencing health status and contact with health services

117

1.33

0.72

1.1

1.2

—

17.89

u/ml

—

Emotionally unstable personality disorder

151

1.39

0.71

1.1

1.2

—

55.00

—

D07AA Corticosteroids, weak (group I)

169

0.65

0.69

1.0

1.2

—

22.83

u/ml

—

Type 2 diabetes, strict (exclude DM1)

123

629

1.14

0.68

1.1

1.2

16.71

26.84

u/ml

—

Alcohol use disorder, ICD-based

410

1.22

0.67

1.1

1.2

—

31.94

u/ml

—

Corneal ulcer

196

1.33

0.67

1.1

—

25.50

u/ml

—

Follow-up examination after treatment for malignant neoplasms

0.55

0.67

1.2

1.1

—

13.71

—

Mental retardation, excluding more controls

1.79

0.66

1.2

1.1

—

Chondropathies

162

1.36

0.66

1.1

1.2

—

24.60

u/ml

—

Symptoms and signs concerning food and fluid intake

1.57

0.64

1.0

1.1

—

27.40

u/ml

—

Open wound of forearm

1.48

0.64

1.4

1.2

—

22.83

u/ml

—

Recurrent aphthous stomatitis , including avohilmo

146

1.37

0.63

1.2

—

24.25

—

Sequelae of external causes of morbidity and mortality

243

1.28

0.62

1.1

24.40

19.22

u/ml

—

Diabetic neuropathy

1.49

0.62

1.1

1.2

—

18.71

—

Unspecified fall

497

1.18

0.61

1.1

—

31.14

u/ml

—

Polycystic ovarian syndrome, broad definition

156

1.35

0.61

1.1

1.2

—

53.60

u/ml

—

Suicide or other Intentional self-harm

271

1.26

0.60

1.1

—

35.33

—

Malignant neoplasm of other and unspecified female genital organs, including Hilmo

0.00

0.60

0.0

1.3

—

Intestinal adhesions without obstruction

1.54

0.59

1.0

1.2

—

11.00

u/ml

—

Early onset COPD

193

1.30

0.57

1.2

1.1

—

22.13

u/ml

—

Other hearing loss

204

1.28

0.57

1.2

1.1

—

22.30

—

Follicular cysts of skin and subcutaneous tissue

182

0.71

0.53

1.0

1.1

—

25.17

—

Persons with potential health hazards related to socioeconomic and psychosocial circumstances

354

1.20

0.53

1.2

—

37.77

—

Bell's palsy

108

1.39

0.53

1.0

1.1

—

11.20

u/ml

—

Follow-up examination after treatment for conditions other than malignant neoplasms

355

1.16

0.51

1.1

1.2

—

17.19

u/ml

—

Disorders of breast

539

1.14

0.49

1.1

1.2

—

31.22

u/ml

—

Non-invasive ventilation

143

0.72

0.46

1.0

1.2

—

22.63

—

Family history of malignant neoplasm

111

1.35

0.46

1.3

1.2

—

52.50

u/ml

—

Other (not insulin) diabetes medications

122

649

1.10

0.46

1.1

1.2

19.00

25.67

u/ml

—

Polyneuropathies and other disorders of the peripheral nervous system

182

1.26

0.46

1.0

1.1

—

18.89

—

Ganglion

200

1.25

0.46

1.2

1.1

—

36.36

u/ml

—

Erosion of teeth , including avohilmo

320

0.81

0.45

1.1

1.2

—

34.81

u/ml

—

Impingement syndrome of shoulder

187

0.75

0.45

1.1

—

30.17

—

Cervicobrachial syndrome

201

1.24

0.44

1.1

—

36.73

u/ml

—

Other disorders of the genitourinary system

112

1.34

0.44

1.1

—

16.00

—

Fissure and fistula of anal and rectal regions

220

1.23

0.43

1.1

1.2

—

37.50

u/ml

—

All influenza (not pneumonia)

139

1.30

0.43

1.2

—

24.83

—

Type 2 diabetes, definitions combined, including avohilmo

121

637

1.10

0.43

1.1

1.2

16.71

28.00

u/ml

—

Secondary and unspecified malignant neoplasm of lymph nodes

1.43

0.42

1.1

1.2

—

13.60

—

Mixed conductive and sensorineural hearing loss

0.65

0.42

1.0

1.1

—

14.33

u/ml

—

Otitis externa

251

0.80

0.42

1.2

1.1

—

37.73

—

Other menopausal disorders

165

0.81

0.41

1.1

1.2

—

20.83

u/ml

—

Gender identity disorders

0.00

0.41

0.0

1.3

—

Congenital deformities of hip

0.00

0.41

0.0

1.2

—

Human immunodeficiency virus [HIV] disease resulting in other conditions

0.00

0.41

0.0

1.2

—

Human immunodeficiency virus [HIV] disease resulting in other conditions, including avohilmo

0.00

0.41

0.0

1.2

—

Congenital deformities of hip, including avohilmo

0.00

0.41

0.0

1.2

—

Burn and corrosion of hip and lower limb, except ankle and foot

0.00

0.41

0.0

1.1

—

Mental and behabioural disorders of puerperum, not classified elsewhere, excluding more controls

0.00

0.40

0.0

1.2

—

Human immunodeficiency virus [HIV] disease

0.00

0.40

0.0

1.2

—

Human immunodeficiency virus [HIV] disease, including avohilmo

0.00

0.40

0.0

1.2

—

Falls/tendency to fall

147

679

1.08

0.40

1.1

1.2

47.57

24.52

u/ml

—

Impacted teeth

223

1.19

0.38

1.3

1.2

—

29.33

u/ml

—

Malignant neoplasm of kidney, except renal pelvis, including Hilmo

1.36

0.38

1.1

1.2

—

13.60

u/ml

—

Salpingitis and oophoritis

181

0.77

0.38

1.1

—

47.60

u/ml

—

Speech and linguistic disorders

1.29

0.36

1.3

1.2

—

33.20

—

Nonorganic sleeping disorders, excluding more controls

226

1.20

0.35

1.2

—

28.70

u/ml

—

Benign neoplasm: Stomach

0.63

0.35

1.0

1.1

—

17.33

—

Chronic gastritis

217

1.20

0.35

1.1

—

13.22

u/ml

—

Otitis externa, unspecified

123

0.73

0.35

1.3

1.1

—

12.80

—

Other noninflammatory disorders of vulva and perineum

117

1.28

0.35

1.1

—

35.20

u/ml

—

Colonic or urogenital fistula

273

1.17

0.34

1.2

1.1

—

36.00

u/ml

—

Primary gonarthrosis, bilateral

362

1.13

0.34

1.1

—

23.36

u/ml

—

Enthesopathies of lower limb, excluding foot

218

1.19

0.34

1.2

—

39.40

u/ml

—

Superficial injury of abdomen, lower back and pelvis

163

1.23

0.34

1.1

—

22.83

—

Asthma and allergy

134

1.25

0.33

1.2

—

50.20

u/ml

—

COPD, hospital admissions 3, with asthma pneumonia sepsis

163

1.21

0.33

1.1

—

15.71

u/ml

—

Dislocation, sprain and strain of joints and ligaments at neck level

182

1.21

0.33

1.1

1.2

—

47.67

—

Personality disorders, excluding more controls

313

1.15

0.31

1.1

1.2

—

30.81

u/ml

—

Malignant neoplasm of breast, ER-negative, including Hilmo

174

0.81

0.30

1.1

—

13.20

u/ml

—

Cervical disc disorders

315

1.14

0.30

1.1

—

32.00

u/ml

—

Disorders of adult personality and behaviour

344

1.13

0.29

1.1

1.2

—

34.57

u/ml

—

Nontoxic multinodular goitre

152

0.79

0.29

1.2

1.1

—

29.80

u/ml

—

Pedal cyclist injured in other and unspecified transport accidents

119

0.76

0.27

1.1

1.2

—

24.00

—

Personality disorders

318

1.13

0.27

1.1

1.2

—

35.23

u/ml

—

Benign neoplasm: Sigmoid colon

150

0.80

0.27

1.0

1.1

—

18.89

u/ml

—

Malignant neoplasm of urinary organs

1.21

0.26

1.0

1.2

—

13.60

u/ml

—

Malignant neoplasm of head and neck, including Hilmo

0.70

0.26

1.2

—

13.60

—

Malignant neoplasm of urinary organs, including Hilmo

1.30

0.26

1.1

1.2

—

13.60

u/ml

—

Eating disorders

132

1.21

0.25

1.0

1.2

—

23.20

—

Perineal laceration during delivery

224

0.86

0.25

1.1

1.2

—

28.00

u/ml

—

Female infertility, associated with anovulation

114

1.23

0.25

1.1

—

42.50

—

Budesonide

114

1.23

0.25

1.2

—

24.00

—

Ménière disease

1.20

0.25

1.1

—

14.60

u/ml

—

Calcific aortic valvular stenosis, including rheumatic fever

184

0.84

0.24

1.1

—

14.78

—

Calcific aortic valvular stenosis, operated

184

0.84

0.24

1.1

—

14.78

—

Calcific aortic valvular stenosis

184

0.84

0.24

1.1

—

14.78

—

Parkinson's disease, strict definition

1.17

0.24

1.1

1.2

—

13.67

—

Anxiety (asthma-related co-morbidities)

594

1.07

0.24

1.2

—

22.74

u/ml

—

Contact with machinery

0.72

0.24

1.2

1.1

—

11.20

—

Lichen planus, including avohilmo

180

1.17

0.23

1.0

1.1

—

15.13

—

Operations 2 for CAVS

183

0.84

0.23

1.1

—

14.78

—

Calcific aortic valvular stenosis, diagnosis (helper)

183

0.84

0.23

1.1

—

14.78

—

Combinations of oral blood glucose lowering drugs

243

0.86

0.23

1.2

1.1

—

16.56

—

Nasal polyp

179

0.84

0.23

1.1

—

39.50

u/ml

—

Benign neoplasms

132

680

1.06

0.22

1.2

52.83

20.78

u/ml

—

Umbilical hernia

274

0.88

0.22

1.1

—

31.42

u/ml

—

All anxiety disorders

647

1.07

0.22

1.2

—

27.82

u/ml

—

Benign lipomatous neoplasm of skin and subcutaneous tissue of trunk

135

0.81

0.22

1.3

1.1

—

17.33

—

Alzheimer’s disease (Early onset), excluding more controls

0.00

0.21

0.0

1.2

—

Tic and related disorders

0.00

0.21

0.0

1.1

—

Malignant neoplasm of other and unspecified female genital organs

0.00

0.21

0.0

1.4

—

Occupant of special all-terrain or other motor vehicle designed primarily for off-road use, injured in transport accident

0.00

0.21

0.0

1.0

—

Burn and corrosion of shoulder and upper limb, except wrist and hand

0.00

0.21

0.0

1.2

—

Other disorders of the musculoskeletal system and connective tissue

135

1.19

0.21

1.0

1.1

—

16.00

u/ml

—

Injury of muscle and tendon at lower leg level

135

1.19

0.21

1.0

1.1

—

20.33

—

Injury of eye and orbit

135

1.19

0.21

1.1

1.2

—

23.60

u/ml

—

Viral infections of central nervous system, not elsewhere classified/unspecifie, including avohilmod

0.00

0.21

0.0

1.2

—

Tic and related disorders

0.00

0.21

0.0

1.2

—

Congenital obstructive defects of renal pelvis and congenital malformations of ureter

0.00

0.21

0.0

1.2

—

Ventricular septal defect, a heart condition

0.00

0.21

0.0

1.2

—

Coronary artery bypass grafting

100

0.82

0.21

1.1

1.2

—

13.29

—

Melanocytic naevi

344

1.10

0.21

1.2

1.1

—

31.43

u/ml

—

Macular pucker

108

1.20

0.20

1.2

1.1

—

13.86

—

Inguinal hernia

376

1.08

0.20

1.2

—

29.05

u/ml

—

Postpartum haemorrhage due to anatomy

176

0.85

0.19

1.1

1.2

—

52.20

u/ml

—

Embedded and impacted teeth

288

1.10

0.19

1.2

—

43.90

u/ml

—

Polyuria

196

0.87

0.18

1.1

—

15.29

—

Kela-code for severe mental illness

394

0.91

0.18

1.0

1.2

—

29.94

u/ml

—

Other and unspecified polyneuropathies, also in other diseases

157

1.15

0.17

1.1

—

18.71

—

Acute nasopharyngitis (common cold)

109

1.18

0.17

1.3

1.2

—

30.17

u/ml

—

Sudden idiopathic hearing loss

1.22

0.17

1.3

1.1

—

15.60

—

Other strabismus

235

0.89

0.16

1.0

1.1

—

39.67

—

Benign neoplasm: Transverse colon

1.16

0.16

1.0

1.2

—

11.20

u/ml

—

Diseases of external ear

360

0.92

0.16

1.2

1.1

—

32.79

—

Stenosis and insufficiency of lacrimal passages

1.10

0.15

1.0

1.2

—

14.33

u/ml

—

Other congenital malformations, including avohilmo

130

1.15

0.15

1.3

1.2

—

24.60

u/ml

—

Achilles tendinitis

1.21

0.15

1.0

1.2

—

22.60

—

Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances

197

1.12

0.15

1.0

1.2

—

47.67

—

Chronic periodontitis, complicated

541

1.06

0.15

1.1

—

27.33

u/ml

—

Misadventures to patients during surgical and medical care

121

1.16

0.15

1.1

1.2

—

23.40

u/ml

—

Ptosis of eyelid

0.81

0.14

1.1

—

15.60

—

Generalized anxiety disorder

212

0.89

0.14

1.2

—

47.00

—

Allergic contact dermatitis

141

1.14

0.13

1.2

—

27.40

—

Other blood glucose lowering drugs, excl. Insulins

122

1.15

0.13

1.1

—

13.17

—

Stomatitis and related lesions

218

1.10

0.13

1.3

1.1

—

36.60

—

Specific personality disorders

286

1.08

0.13

1.2

1.1

—

35.64

u/ml

—

Benign neoplasm of eye and adnexa

1.17

0.13

1.3

1.1

—

14.60

u/ml

—

Superficial injury of forearm

117

0.85

0.13

1.0

1.2

—

22.83

—

Poisoning by drugs, medicaments and biological substances

273

0.92

0.13

1.1

1.2

—

33.15

—

Tonsillectomy and adenotomy

546

1.04

0.12

1.2

—

30.87

u/ml

—

Injuries to the elbow and forearm

723

0.96

0.11

1.2

—

28.81

u/ml

—

Benign leiomyoma with endometriosis

147

0.88

0.11

1.3

1.1

—

61.80

—

Car occupant injured in other and unspecified transport accidents

211

1.09

0.11

1.1

1.2

—

44.63

u/ml

—

Secondary malignant neoplasm of respiratory and digestive organs, including Hilmo

156

0.90

0.10

1.0

1.2

—

13.60

u/ml

—

Allergic asthma (mode), excluding more controls

245

1.08

0.10

1.1

—

50.50

u/ml

—

Alcohol dependence

222

1.08

0.10

1.1

—

16.78

u/ml

—

Other benign neoplasms of skin

361

0.94

0.09

1.1

—

37.27

u/ml

—

Parkinson's disease

1.15

0.09

1.1

—

16.14

—

Unspecified lump in breast

176

0.91

0.09

1.1

—

41.00

u/ml

—

Injury of muscle and tendon at wrist and hand level

124

0.89

0.09

1.2

1.1

—

17.50

u/ml

—

Female infertility, cervical, vaginal, other or unspecified origin

224

1.06

0.08

1.1

1.2

—

31.30

u/ml

—

Other problems related to primary support group, including family circumstances

123

1.11

0.08

1.1

1.2

—

24.60

—

Retinal detachment with retinal break

1.12

0.07

1.1

—

11.20

u/ml

—

Assault

147

1.09

0.07

1.2

—

31.57

—

Female infertility

229

1.05

0.07

1.2

—

31.30

u/ml

—

Other disorders of breast

163

0.92

0.07

1.1

—

60.20

—

Malignant melanoma

132

0.91

0.06

1.1

—

13.60

—

Panic disorder

183

0.93

0.06

1.1

—

41.86

—

Acute pharyngitis

166

1.07

0.06

1.2

—

45.25

—

Other anxiety disorders

537

1.03

0.06

1.2

—

30.50

u/ml

—

Pain associated with micturition

121

0.91

0.06

1.4

1.1

—

16.33

—

Female genital prolapse

175

0.95

0.05

1.1

—

28.29

u/ml

—

Acute appendicitis, with complications

182

0.93

0.05

1.0

1.1

—

19.43

—

Poisoning by medicine

253

0.95

0.05

1.1

1.2

—

35.11

—

Nonorganic sleeping disorders

258

1.05

0.04

1.2

—

37.22

u/ml

—

Allergic asthma (mode)

252

1.05

0.04

1.1

—

42.20

u/ml

—

Fracture at wrist and hand level

361

0.97

0.04

1.2

—

26.76

u/ml

—

Disorders of psychological development

103

1.08

0.03

1.2

—

33.20

—

Seborrhoeic keratosis

191

1.05

0.03

1.2

1.1

—

22.67

u/ml

—

Benign neoplasm of other and unspecified endocrine glands

122

1.07

0.02

1.1

—

17.33

—

Fracture of foot, except ankle

289

0.97

0.02

1.3

1.1

—

36.69

u/ml

—

Special screening examination for other diseases and disorders

132

1.06

0.02

1.0

1.1

—

14.33

—

Burns and corrosions

148

0.95

0.02

1.1

1.2

—

22.83

—

Benign neoplasm of other and ill-defined parts of digestive system

158

0.95

0.02

1.1

—

15.13

u/ml

—

Prolonged pregnancy

177

0.96

0.01

1.2

—

25.00

u/ml

—

Fracture of forearm

537

0.99

0.01

1.2

1.1

—

29.21

u/ml

—

Exposure to other specified factors

100

851

1.01

0.01

1.1

1.2

—

27.14

u/ml

—

Parkinson's disease, including avohilmo

1.06

0.01

1.1

—

16.14

—

Benign lipomatous neoplasm

282

0.99

0.00

1.2

1.1

—

32.64

u/ml

—

Malignant melanoma of skin, including Hilmo

123

0.98

0.00

1.1

1.2

—

13.60

—

Organic, including symptomatic, mental disorders

291

0.99

0.00

1.2

1.1

15.20

25.36

u/ml

—

Secondary and unspecified malignant neoplasm of lymph nodes, including Hilmo

126

1.03

0.00

1.1

1.2

—

13.60

—

Malignant melanoma, including Hilmo

144

0.97

0.00

1.1

1.2

—

13.60

—

Chalazion

115

0.96

0.00

1.1

1.2

—

24.00

—

Melanocytic naevi of trunk

125

1.04

0.00

1.0

1.2

—

24.00

—

Burns and corrosions of external body surface, specified by site

113

0.97

0.00

1.1

1.2

—

12.80

—

Strabismus

278

1.00

0.00

1.0

1.1

—

34.00

—

Bipolar affective disorders

218

1.01

0.00

1.0

1.2

—

22.45

—

Benign neoplasm: Skin of eyelid, including canthus

129

1.01

0.00

1.0

1.1

—

16.00

u/ml

—

Other disorders of eye and adnexa

156

1.03

0.00

1.0

1.1

—

23.29

—

Blepharochalasis

243

0.99

0.00

1.1

—

21.09

u/ml

—

Superficial injury of head

227

1.01

0.00

1.3

1.1

—

37.30

u/ml

—

Precocious puberty

0.00

0.0

1.0

—

Intentional self-harm by jumping from a high place

0.00

0.0

1.0

—

Delayed puberty

0.00

0.0

1.0

—

Pedal cyclist injured in collision with other pedal cycle or other nonmotor vehicle

0.00

0.0

1.1

—

Early syphilis

0.00

0.0

1.0

—

Narcolepsy and cataplexy

0.00

0.0

1.2

—

Tic disorders

0.00

0.0

1.1

—

Neonatal jaundice from other and unspecified causes

0.00

0.0

1.6

—

Orthopaedic devices associated with adverse incidents

0.00

0.0

1.0

—

Congenital malformations of eyelid, lacrimal apparatus and orbit

0.00

-0.00

0.0

1.2

—

Inflammation of lacrimal passages (chronic)

0.00

-0.00

0.0

1.3

—

Cellulitis of external ear

0.00

-0.00

0.0

1.1

—

Benign neoplasm: Peripheral nerves and autonomic nervous system

0.00

-0.00

0.0

1.1

—

Benign neoplasm: Tonsil

0.00

-0.00

0.0

1.3

—

Serous carcinoma of ovary

0.00

-0.00

0.0

1.4

—

Other specified and unspecified disorders of eyelid

0.00

-0.00

0.0

1.0

—

Viral infections of central nervous system, not elsewhere classified/unspecified

0.00

-0.00

0.0

1.3

—

Other disorders affecting eyelid function

0.00

-0.00

0.0

1.4

—

Acute myringitis

0.00

-0.00

0.0

1.0

—

Other injuries of upper limb, level unspecified

0.00

-0.00

0.0

1.0

—

Other and unspecified disorders of psychological development

0.00

-0.00

0.0

1.0

—

Type 1 diabetes, wide definition, subgroup 2

0.00

-0.00

0.0

1.0

—

Use of rotigotine

0.00

-0.00

0.0

1.2

—

Congenital malformations of the respiratory system

0.00

-0.00

0.0

1.2

—

Accessory breast

0.00

-0.00

0.0

1.4

—

Ankyloglossia

0.00

-0.00

0.0

1.2

—

Caries in Clefts patients

0.00

-0.00

0.0

1.0

—

Unspecified urinary incontinence

0.96

-0.00

1.1

—

13.40

—

Congenital malformations of eyelid, lacrimal apparatus and orbit, including avohilmo

0.00

-0.00

0.0

1.2

—

Other congenital malformations of tongue, mouth and pharynx

0.00

-0.00

0.0

1.1

—

Other congenital malformations of tongue, mouth and pharynx, including avohilmo

0.00

-0.00

0.0

1.1

—

Disorder of thyroid, unspecified

0.00

-0.00

0.0

1.1

—

Migraine with aura, drug-induced

0.00

-0.00

0.0

1.4

—

Constitutional tall stature

0.00

-0.00

0.0

1.0

—

Secondary parkinsonism, excluding more controls

0.00

-0.00

0.0

1.2

—

Non-Hodgkin lymphoma, all, including Hilmo

0.91

-0.00

1.0

1.2

—

13.60

—

Congenital vesicoureteral reflux

0.00

-0.00

0.0

1.2

—

Melanocytic naevi of lip

0.00

-0.00

0.0

1.3

—

Other benign neoplasm of uterus: Corpus uteri

0.00

-0.00

0.0

1.3

—

Endometroid carcinoma of ovary

0.00

-0.00

0.0

1.2

—

Seminoma of testis

0.00

-0.00

0.0

1.0

—

Neuroendocrine tumor and carcinoma of pancreas

0.00

-0.00

0.0

1.0

—

Abnormal findings on diagnostic imaging of breast

0.00

-0.00

0.0

1.3

—

Fetus and newborn affected by maternal factors and by complications of pregnancy, labour and delivery

0.00

-0.00

0.0

1.6

—

Malignant neoplasm of testis

0.00

-0.00

0.0

1.0

—

Malignant melanoma of skin

100

1.00

-0.00

1.1

1.2

—

13.60

—

Seminoma of testis, including Hilmo

0.00

-0.00

0.0

1.0

—

Vaginal lichen planus

0.00

-0.00

0.0

1.2

—

0.00

-0.00

0.0

1.0

—

Contact with hypodermic needle

0.00

-0.00

0.0

1.0

—

Endometroid carcinoma of ovary, including Hilmo

0.00

-0.00

0.0

1.2

—

Malignant neoplasm of vulva

0.00

-0.00

0.0

1.3

—

Operations for atrial fibrillation

0.00

-0.00

0.0

1.0

—

Trichomoniasis, including avohilmo

0.00

-0.00

0.0

1.2

—

Early syphilis, including avohilmo

0.00

-0.00

0.0

1.0

—

Acute poliomyelitis

0.00

-0.00

0.0

1.1

—

Acute poliomyelitis, including avohilmo

0.00

-0.00

0.0

1.1

—

Atypical virus infections of central nervous system, including avohilmo

0.00

-0.00

0.0

1.2

—

Injury of nerves at ankle and foot level

0.00

-0.00

0.0

1.2

—

Contact with lifting and transmission devices, not elsewhere classified

0.00

-0.00

0.0

1.1

—

Osteonecrosis due to drugs

0.00

-0.00

0.0

1.0

—

Synovial hypertrophy, not elsewhere classified

0.00

-0.00

0.0

1.3

—

Iliotibial band syndrome

0.00

-0.00

0.0

1.4

—

Contracture of joint

0.00

-0.00

0.0

1.4

—

Osteochondrosis of ankle, juvenile

0.00

-0.00

0.0

1.0

—

Palindromic rheumatism

0.00

-0.00

0.0

1.2

—

Scoliosis

0.99

-0.00

1.1

1.2

—

28.60

—

Other factor of the environment

0.00

-0.00

0.0

1.2

—

Poisoning by and exposure to other and unspecified chemicals and noxious substances, undetermined intent

0.00

-0.00

0.0

1.1

—

Atypical virus infections of central nervous system

0.00

-0.00

0.0

1.2

—

Lifestyle-related condition

0.00

-0.00

0.0

1.2

—

Impacted maxillary canine

0.00

-0.00

0.0

1.0

—

Sequelae of intentional self-harm, assault and events of undetermined intent

0.00

-0.00

0.0

1.0

—

Exclusion endpoint for supernumerary teeth

0.00

-0.00

0.0

1.0

—

Examination and encounter for administrative purposes

0.89

-0.00

1.0

1.1

—

15.60

—

Other disorders originating in the perinatal period

0.00

-0.00

0.0

1.2

—

Congenital dislocation of hip, unilateral

0.00

-0.00

0.0

1.0

—

Congenital malformations of the respiratory system, including avohilmo

0.00

-0.00

0.0

1.3

—

Mandibular prognathia AND surgery (LeFortI or BSSO), including avohilmo

0.00

-0.00

0.0

1.0

—

≡ Risteys

R14

FinnGen R13 + FinRegistry

FinnGen R12 + FinRegistry

FinnGen R11 + FinRegistry

FinnGen R10 + FinRegistry

FinnGen R10

FinnGen R9

FinnGen R8

FinnGen R7

FinnGen R6

FinnGen R5

FinnGen R4

FinnGen R3

Beta 2 glycoprotein 1 IgM Ab [Units/volume] in Serum

Coding

Definition

OMOP mapping QC

Cohort

Year of birth distribution

Age at first measurement

Age at last measurement

Age at start of registry

Duration from first to last measurement

Statistics

Number of measurements over the years

Number of measurements per person

Distribution of lab values

Value range per person

LabWAS